Number of pages: 120 | Report Format: PDF | Published date: 28 January, 2022
Historical Years – 2018 & 2019 | Base Year – 2020 | Forecasted Years – 2021-2031
The global pediatric neuroblastoma treatment market was pegged at US$ 759.5 million in 2020 and is expected to witness a CAGR of 8.5% during the forecast period.
Market Fundamentals
Neuroblastoma is a cancerous tumor that begins in the nerve tissue of infants and very young children. It is the most common extracranial solid tumor of infancy. It is an embryonal malignancy of the sympathetic nervous system arising from neuroblasts (pluripotent sympathetic cells). Infants usually develop a form of neuroblastoma that is less aggressive and can mature into benign tumors. Children over 12 to 18 months usually develop a more aggressive form of neuroblastoma that often invades vital structures and may spread throughout the body. The majority of cases affect young children before school age, with some cases beginning before birth and unusual cases first arising as late as adolescence.
[79454324]
Market Dynamics
The global pediatric neuroblastoma treatment market is mainly driven by the rising prevalence of neuroblastoma worldwide, strong product pipeline, increasing awareness programs, and growing public and private funding for R&D activities. Furthermore, growing collaboration among the prominent players and various organizations for R&D activities is also likely to play a pivotal role in contributing to the growth of the market globally. However, the high cost of the therapy and the adverse effects related to treatment are likely to restrain the market growth to a certain extent.
Market Ecosystem
The global pediatric neuroblastoma treatment market has been analyzed from four perspectives: Treatment Type, Risk Group, End User, and Region.
Pediatric Neuroblastoma Treatment Market by Treatment Type
Based on treatment type, the pediatric neuroblastoma treatment market has been segmented into chemotherapy, immunotherapy, targeted therapy, radiation therapy, and others (hormonal therapy, stem cell transplants, targeted therapy, etc.). The chemotherapy segment dominated the market with the largest share in 2020. The large share of the chemotherapy segment is attributed to the fact that it is the most common form of treatment prescribed for neuroblastoma. It can also be used before surgery to shrink the tumor or after surgery to destroy any remaining cancer cells.
Pediatric Neuroblastoma Treatment Market by Risk Group
[73452424]
Based on risk group, the pediatric neuroblastoma treatment market has been segmented into low risk, intermediate-risk, and high risk. The high risk segment dominated the market with the largest share in 2020, owing to the high prevalence rate of neuroblastoma in this segment. High-risk neuroblastoma accounts for approximately 70% of total neuroblastoma cases.
Pediatric Neuroblastoma Treatment Market by End User
Based on end-user, the pediatric neuroblastoma treatment market has been segmented into hospitals, cancer specialty centers, and others (ambulatory care centers, clinics, etc.). The hospital segment dominated the market with the largest share in 2020. The large share of this segment can be attributed to the high volume of pediatric patients visiting hospitals for diagnosis and treatment of neuroblastoma.
Pediatric Neuroblastoma Treatment Market by Region
Based on region, the global pediatric neuroblastoma treatment market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World (ROW). North America dominated the pediatric neuroblastoma treatment market, followed by the Asia Pacific. The large share of North America in the global market can largely be attributed to advanced healthcare infrastructure, rising prevalence of pediatric neuroblastoma, and relatively high volume of pediatric patients at the hospitals admitted for the treatment of neuroblastoma.
Competitive Landscape
Some of the prominent players operating in the pediatric neuroblastoma treatment market includes:-
Strategic Developments
Report Attribute |
Details |
Historical Period |
2018 & 2019 |
Base year for estimation |
2020 |
Forecast period |
2021-2031 |
Market size in 2020 |
USD 759.5 million |
Market size in 2031 |
USD 1,863.1 million |
Growth Rate |
8.5% |
Segments covered |
Treatment Type, Risk Group and End User |
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (RoW) |
The global pediatric neuroblastoma treatment market was estimated to clock at US$ 759.5 million in 2020
The pediatric neuroblastoma treatment market is projected to reach US$ 1,863.1 million by 2031
The global pediatric neuroblastoma treatment market is mainly driven by the rising prevalence of neuroblastoma worldwide, strong product pipeline, increasing awareness programs, and growing public and private funding for R&D activities. Furthermore, growing collaboration among the prominent players and various organizations for R&D activities is also likely to play a pivotal role in contributing to the growth of the market globally.
Bayer AG, Pfizer Inc, Apeiron Biologics AG, United Therapeutics Corporation, Y-mAbs Therapeutics, Inc, Cellectar Biosciences, Inc, Clarity Pharmaceuticals, Provectus Biopharmaceuticals, Inc, Scorpion Therapeutics, among others
The growth rate of pediatric neuroblastoma treatment market is CAGR of 8.5% between 2021-2031
North America held the largest market share of the global pediatric neuroblastoma treatment market in 2020
*Insights on financial performance is subject to availability of information in the public domain
Growth+Reports can now be customized as per client’s needs through GRG Health’s primary research and knowledge services capabilities
GRG Health’s unique GrowthMIX approach and robust research methodology helps us deliver unique & meaningful insights to our clients and uncover trends that won’t meet the standard approach